Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Large cohort study demonstrates DOAC safety vs. warfarin
Vinogradova Y et al. BMJ 2018;362:k2505.
Key clinical point: In a real world, primary care setting, direct oral anticoagulants were associated with decreased bleeding risk versus warfarin.
Major finding: Apixaban was linked with an adjusted 34% decreased risk of major bleeding in patients with AF and a 40% lower risk in those prescribed anticoagulants for other causes, compared with warfarin.
Study details: A retrospective cohort study representing 196,061 patients from two U.K. primary care databases.
Disclosures: The study was supported by a grant from the National Institute for Health Research. The investigators had no relevant disclosures.
Source: Vinogradova Y et al. BMJ 2018;362:k2505.
Vinogradova Y et al. BMJ 2018;362:k2505.